Correction to: Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017

John Greenwood; Margareta Hammarlund-Udenaes; Hazel C Jones; Alan W Stitt; Roosmarijn E Vandenbroucke; Ignacio A Romero; Matthew Campbell; Gert Fricker; Birger Brodin; Heiko Manninga; Pieter J Gaillard; Markus Schwaninger; Carl Webster; Krzysztof B Wicher; Michel Khrestchatisky

doi:10.1186/s12987-017-0086-x

Correction to: Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017

Fluids Barriers CNS. 2018 Jan 12;15(1):3. doi: 10.1186/s12987-017-0086-x.

Authors

John Greenwood¹, Margareta Hammarlund-Udenaes², Hazel C Jones³, Alan W Stitt⁴, Roosmarijn E Vandenbroucke^{5

6}, Ignacio A Romero⁷, Matthew Campbell⁸, Gert Fricker⁹, Birger Brodin¹⁰, Heiko Manninga¹¹, Pieter J Gaillard¹², Markus Schwaninger¹³, Carl Webster¹⁴, Krzysztof B Wicher¹⁵, Michel Khrestchatisky^{16

17}

Affiliations

¹ Institute of Ophthalmology, University College London, London, EC1V 9EL, UK.
² Department of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden.
³ Gagle Brook House, Chesterton, Bicester, OX26 1UF, UK. hazelcjones@btinternet.com.
⁴ Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
⁵ Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
⁶ VIB-UGent Center for Inflammation Research, VIB, Ghent, Belgium.
⁷ School of Life, Health and Chemical Sciences, Open University, Milton Keynes, UK.
⁸ Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.
⁹ Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls University, Heidelberg, Germany.
¹⁰ Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
¹¹ NEUWAY Pharma GmbH, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.
¹² 2-BBB Medicines BV, Leiden, Netherlands.
¹³ Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.
¹⁴ Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
¹⁵ Ossianix Inc., Stevenage, UK.
¹⁶ CNRS, NICN, Aix Marseille Univ, Marseille, France.
¹⁷ Vect-Horus, Faculte de Medecine Nord, 51 Boulevard Pierre Dramard, Marseille, France.

Abstract

After publication of the article [1], it has been brought to our attention that there are some errors in the formatting of names in the final version of the article.

Publication types

Published Erratum